Carteolol
As of the edition of 20 October 2026, Carteolol is a small molecule: marketed, first approved in 1985 (FR); acts on ADRB1, ADRB2 and ADRB3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Small molecule
- Brand name
- Cartrol
- First approved
- 20 February 1985 (FR)
- Approvals on record
- 7 in 4 regions
- Holder of the most recent approval
- Otsuka; 5 holders in all
- Registered trials
- 1, 0 stopped early
- Disease areas
- Eye
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Carteolol.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 1 |